Navigation Links
Dr. Paul Billings joins Trovagene's Scientific Advisory Board
Date:11/19/2012

hool, Stanford School of Medicine and the University of California, Berkeley, and has served as a physician at a number of medical centers throughout the country, including the University of California, San Francisco. Dr. Billings holds an M.D. from Harvard Medical School and a Ph.D. in immunology, also from Harvard University.

About Trovagene, Inc.

Headquartered in San Diego, California, Trovagene is developing its patented technology for the detection of transrenal DNA and RNA, short nucleic acid fragments, originating from normal and diseased cell death that cross the kidney barrier and can be detected in urine.  Trovagene is leveraging its intellectual property in oncogene mutations via out-licensing and use of its transrenal technologies to extend oncogene mutation detection using urine as a sample.  As a non-invasive and abundant sample, urine may overcome many of the cost and collection challenges associated with biopsy, as well as the volume limitations of blood.

Trovagene has a strong patent position as it relates to transrenal molecular testing. It has U.S. and European patent applications and issued patents that cover testing for HPV and other infectious diseases, cancer, transplantation, prenatal and genetic testing. In addition, it owns worldwide rights to nucleophosmin-1 (NPM1), an informative biomarker for acute myeloid leukemia (AML) and mutations in the SF3B1 gene, which have been shown to be associated with chemotherapy response in chronic lymphocytic leukemia (CLL) patients.

Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as "anticipate," "believe," "forecast," "estimated" and "intend," among others. These forward-looking statements are based on Trovagene's current expectations and actual results could differ materially. There are a number o
'/>"/>

SOURCE Trovagene, Inc.
Copyright©2012 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Nutrilys Del Mar Joins Health Forces With LAPD Underwater Dive Unit
2. Keith McCormick Joins Trovagene, Inc. as Head of Commercial Operations
3. Aethlon Medical Note: Marc Robins Joins the Aethlon Team
4. Effie Toshav Joins Fenwick - Broadens Life Sciences Service Platform
5. David F. Harty Joins Systech International as Vice President
6. Jim DuCharme Joins Prime Therapeutics as Chief Financial Officer
7. Ted Pacha Joins Pinnaclife as President of its Healthcare Distribution Division
8. Rittal Corp. Joins the HP ProActive Insight Architecture Alliance
9. Anthony Creed Joins DDSTUDIO As GM, Experience Design
10. IntelliCell Announces Dr. Arnold I. Caplan Joins Scientific Advisory Board
11. American Society of Hematology joins European Hematology Association, Patient Groups in Issuing International Call to Action to Alleviate Drug Shortages
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... 24 de mayo de 2013  Volcano Corporation ... y fabricante de herramientas de precisión para terapia ... de la enfermedad vascular periférica y coronaria, anunció ... Ad enosine V asodilator I ndependent ... la sesión de ensayo clínico hot line late ...
(Date:5/23/2013)... -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) announced ... Chief Executive Officer of Neurocrine Biosciences, will be presenting at ... Conference in Boston.   The live presentation takes ... / 8:20 a.m. Pacific Time.  The presentation will be webcast ... http://www.neurocrine.com . If you are unable to ...
(Date:5/23/2013)... , May 23, 2013 Amgen (NASDAQ: ... th Annual  Healthcare Conference on Thursday, May 30, 2013, ... , beginning at 9:20 a.m. Eastern Daylight Time. ... Amgen, will present at the conference. Live audio of the ... website, www.amgen.com , under Investors. A replay of the ...
Breaking Medicine Technology:Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 2Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 3Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 4Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 5Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 6
... Radiation Therapy Services Holdings, Inc. ("Radiation Therapy Services" or the ... the Wells Fargo Securities 2011 Healthcare Conference on Wednesday, June ... being held at the Intercontinental Hotel in Boston, MA. ... be available by visiting the Events section of the Company,s ...
... N.J., June 17, 2011 Affineti Biologics has received ... Capital Group (FVCG) to advance its research in the ... discoveries in oral biology and dental medicine. ... company invested in Affineti because positive results from studies ...
Cached Medicine Technology:Foundation Venture Capital Group Invests in Company Developing Plaque-Reducing Dental Hygiene Products 2
(Date:5/23/2013)... (PRWEB) May 23, 2013 Da Vinci ... in a trial in Washington State May 23, according ... clients in surgical robot lawsuits , expresses disappointment ... da Vinci lawsuits to not read a single verdict ... case (Estate of Fred E. Taylor v. Intuitive Surgical ...
(Date:5/23/2013)... (PRWEB) May 23, 2013 Amirsys, ... comprehensive radiology learning environment for all resident levels ... and assessments, transforms the learning experience from case-based ... , “Until RADPrimer 3.0, RADPrimer heavily ... none,” comments Dr. B.J. Manaster, Professor of Radiology ...
(Date:5/23/2013)... HealthDay Reporter , , THURSDAY, May 23 (HealthDay News) -- ... treat hip and knee osteoarthritis may have an unexpected ... a small new study of older adults suggests. ... intraocular pressure (IOP) or pressure inside the eye. Left ... blindness. In the new study of ...
(Date:5/23/2013)... News) -- A modified version of the polio ... preliminary research suggests. Scientists at Duke Cancer ... PVSRIPO, uses an engineered form of the virus ... cancer cells. The therapy shows promise in the ... brain tumor, they said. "These early results ...
(Date:5/23/2013)... eat at fast-food restaurants are consuming significantly more calories ... offenders, a new study found. "Teens underestimate the ... as 34 percent, parents of school-age children by as ... as 20 percent," study lead researcher, Dr. Jason Block, ... Johnson Foundation, which helped fund the study. ...
Breaking Medicine News(10 mins):Health News:Da Vinci Surgical Robot Lawsuit News: Rottenstein Law Group LLP Comments on Intuitive Win in Negligent Training Trial 2Health News:RADPrimer 3.0 Introduces Comprehensive Radiology Training Curriculum 2Health News:Glucosamine Supplements Tied to Risk of Eye Condition 2Health News:Glucosamine Supplements Tied to Risk of Eye Condition 3Health News:Modified Polio Virus May Help Fight Brain Tumors, Study Suggests 2Health News:How Many Calories in Your Fast-Food Meal? Guess Again 2
... more clinical preventive services, dedicate funding source to public ... 11 Partnership for Prevention today unveiled health ... and health promotion efforts to tackle the chronic diseases ... , Under these proposals, federally ...
... Inc. (Nasdaq: PTIE ) has received a Complete Response ... New Drug Application (NDA) for REMOXY(R), an abuse-resistant controlled-release form of ... the NDA is not approved in its present form. ... non-clinical data will be required to support the approval of REMOXY. ...
... touted as the "cure" for health care, but a new ... that implementation of technology and related devices is not a ... safety of patient care. , , ... to understanding when a technology may (or may not) be ...
... Dental Management,Services, Inc. (Nasdaq: BDMS ), operators ... The Company,s board of directors,has declared a quarterly ... stock.,The dividend is payable January 9, 2009, to shareholders ... Birner Dental Management Services, Inc. acquires, develops, ...
... agonists may cause asthma problems and death, agency officials ... of four asthma medications will be weighed by a U.S. ... hearings end Thursday. , The controversy over these drugs has ... recently calling for banning the use of these drugs for ...
... PRA International, a leading,Clinical Research Organization, announces ... Mexico. With years of long-standing South American ... The region,s existing base of clinical,sites with expertise ... to PRA,s therapeutic focus. The expansion is ...
Cached Medicine News:Health News:Partnership for Prevention Offers Health Reform Recommendations to Congress 2Health News:Partnership for Prevention Offers Health Reform Recommendations to Congress 3Health News:Pain Therapeutics Receives Complete Response Letter From FDA for REMOXY(R) 2Health News:Pain Therapeutics Receives Complete Response Letter From FDA for REMOXY(R) 3Health News:Joint Commission Alert: Prevent Technology-Related Health Care Errors 2Health News:Joint Commission Alert: Prevent Technology-Related Health Care Errors 3Health News:FDA Panel Mulls Safety of Asthma Meds 2Health News:FDA Panel Mulls Safety of Asthma Meds 3Health News:PRA International Expands Operations in Mexico 2
... provides a simple, fast and cost-effective method ... samples. This system utilizes guanidine thiocyanate and ... and denature proteins. Purified viral RNA is ... and RNase protection assays. This system is ...
... The Titertek MAP-C2 is designed for ... the instrument is the S60 Stacker that ... removable magazines. The MAP-C2 base model is ... assembly. Auxiliary Digiflex pipetting units may be ...
Grab one and go, One of the smallest handheld oximeters available, Datex-Ohmeda s TuffSat is the ideal spot-check solution for hospital, home care, transport, and EMS. TuffSat comes fully loaded wi...
The IL 682 is the Gold Standard for CO-Oximetry analysis....
Medicine Products: